NCT01560884View on ClinicalTrials.gov

Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
SafetyPhosphate Binding Capacity
Interventions
DRUG

Renazorb 1500 mg/day

Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo

DRUG

Renazorb 3000 mg/day

Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo

DRUG

Renazorb 4500 mg/day

Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo

DRUG

Renazorb 6000 mg/day

Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo

Trial Locations (1)

21225

PAREXEL International - Baltimore Early Phase Clinical Unit, Baltimore

All Listed Sponsors
lead

Spectrum Pharmaceuticals, Inc

INDUSTRY

NCT01560884 - Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb | Biotech Hunter | Biotech Hunter